Biologic targeted therapy in allergic asthma

Jeffrey B. Bice, Evelyn Leechawengwongs, Anthony Montanaro

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective To review the structure, function, clinical utility, and safety of current biologic targeted therapies being used for the treatment of asthma. Data Sources Medical literature obtained from PubMed and OVID searches from June to November 2013. Study Selections Studies were selected based on article impact, relevance, and clinical significance. Particular emphasis was placed on articles discussing therapies targeted at IgE, interleukin (IL)-4, IL-4 receptor, IL-5, IL-13, tumor necrosis factor-α, CRTh2, and toll-like receptors 7 and 9. Results Since the approval of omalizumab in 2003, the development of biologic asthma therapies has grown at a remarkable pace. With approximately 30 drugs currently in clinical trials and dozens more in development, the future of asthma biologic therapies is promising. Despite several well-publicized setbacks, researchers remain focused on elucidating the complex pathophysiology of asthma. The hope is that asthma biologic therapies will eventually be tailored to an individual's asthma phenotype. With more than 300 million people worldwide affected by asthma and with roughly 5% to 10% of this population living with severe, uncontrolled asthma, the need for new biologic therapies is great. Conclusion The introduction of each new biologic therapy into clinical trials has been associated with great anticipation, but the outcome of these trials, in many cases, has led to disappointment. Given the lack of overwhelming positive responses, these results have emphasized that asthma is a complex clinical syndrome with multiple underlying genotypes and clinical phenotypes. It has become abundantly clear that it is very unlikely that there is one "magic bullet" to cure all patients with asthma.

Original languageEnglish (US)
Pages (from-to)108-115
Number of pages8
JournalAnnals of Allergy, Asthma and Immunology
Volume112
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Biological Therapy
Asthma
Toll-Like Receptor 7
Clinical Trials
Interleukin-4 Receptors
Toll-Like Receptor 9
Phenotype
Magic
Interleukin-13
Information Storage and Retrieval
Interleukin-5
PubMed
Interleukin-4
Immunoglobulin E
Tumor Necrosis Factor-alpha
Genotype
Research Personnel
Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Biologic targeted therapy in allergic asthma. / Bice, Jeffrey B.; Leechawengwongs, Evelyn; Montanaro, Anthony.

In: Annals of Allergy, Asthma and Immunology, Vol. 112, No. 2, 02.2014, p. 108-115.

Research output: Contribution to journalArticle

Bice, Jeffrey B. ; Leechawengwongs, Evelyn ; Montanaro, Anthony. / Biologic targeted therapy in allergic asthma. In: Annals of Allergy, Asthma and Immunology. 2014 ; Vol. 112, No. 2. pp. 108-115.
@article{6cefa172996e4836bbd7e69f57b3575d,
title = "Biologic targeted therapy in allergic asthma",
abstract = "Objective To review the structure, function, clinical utility, and safety of current biologic targeted therapies being used for the treatment of asthma. Data Sources Medical literature obtained from PubMed and OVID searches from June to November 2013. Study Selections Studies were selected based on article impact, relevance, and clinical significance. Particular emphasis was placed on articles discussing therapies targeted at IgE, interleukin (IL)-4, IL-4 receptor, IL-5, IL-13, tumor necrosis factor-α, CRTh2, and toll-like receptors 7 and 9. Results Since the approval of omalizumab in 2003, the development of biologic asthma therapies has grown at a remarkable pace. With approximately 30 drugs currently in clinical trials and dozens more in development, the future of asthma biologic therapies is promising. Despite several well-publicized setbacks, researchers remain focused on elucidating the complex pathophysiology of asthma. The hope is that asthma biologic therapies will eventually be tailored to an individual's asthma phenotype. With more than 300 million people worldwide affected by asthma and with roughly 5{\%} to 10{\%} of this population living with severe, uncontrolled asthma, the need for new biologic therapies is great. Conclusion The introduction of each new biologic therapy into clinical trials has been associated with great anticipation, but the outcome of these trials, in many cases, has led to disappointment. Given the lack of overwhelming positive responses, these results have emphasized that asthma is a complex clinical syndrome with multiple underlying genotypes and clinical phenotypes. It has become abundantly clear that it is very unlikely that there is one {"}magic bullet{"} to cure all patients with asthma.",
author = "Bice, {Jeffrey B.} and Evelyn Leechawengwongs and Anthony Montanaro",
year = "2014",
month = "2",
doi = "10.1016/j.anai.2013.12.013",
language = "English (US)",
volume = "112",
pages = "108--115",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "2",

}

TY - JOUR

T1 - Biologic targeted therapy in allergic asthma

AU - Bice, Jeffrey B.

AU - Leechawengwongs, Evelyn

AU - Montanaro, Anthony

PY - 2014/2

Y1 - 2014/2

N2 - Objective To review the structure, function, clinical utility, and safety of current biologic targeted therapies being used for the treatment of asthma. Data Sources Medical literature obtained from PubMed and OVID searches from June to November 2013. Study Selections Studies were selected based on article impact, relevance, and clinical significance. Particular emphasis was placed on articles discussing therapies targeted at IgE, interleukin (IL)-4, IL-4 receptor, IL-5, IL-13, tumor necrosis factor-α, CRTh2, and toll-like receptors 7 and 9. Results Since the approval of omalizumab in 2003, the development of biologic asthma therapies has grown at a remarkable pace. With approximately 30 drugs currently in clinical trials and dozens more in development, the future of asthma biologic therapies is promising. Despite several well-publicized setbacks, researchers remain focused on elucidating the complex pathophysiology of asthma. The hope is that asthma biologic therapies will eventually be tailored to an individual's asthma phenotype. With more than 300 million people worldwide affected by asthma and with roughly 5% to 10% of this population living with severe, uncontrolled asthma, the need for new biologic therapies is great. Conclusion The introduction of each new biologic therapy into clinical trials has been associated with great anticipation, but the outcome of these trials, in many cases, has led to disappointment. Given the lack of overwhelming positive responses, these results have emphasized that asthma is a complex clinical syndrome with multiple underlying genotypes and clinical phenotypes. It has become abundantly clear that it is very unlikely that there is one "magic bullet" to cure all patients with asthma.

AB - Objective To review the structure, function, clinical utility, and safety of current biologic targeted therapies being used for the treatment of asthma. Data Sources Medical literature obtained from PubMed and OVID searches from June to November 2013. Study Selections Studies were selected based on article impact, relevance, and clinical significance. Particular emphasis was placed on articles discussing therapies targeted at IgE, interleukin (IL)-4, IL-4 receptor, IL-5, IL-13, tumor necrosis factor-α, CRTh2, and toll-like receptors 7 and 9. Results Since the approval of omalizumab in 2003, the development of biologic asthma therapies has grown at a remarkable pace. With approximately 30 drugs currently in clinical trials and dozens more in development, the future of asthma biologic therapies is promising. Despite several well-publicized setbacks, researchers remain focused on elucidating the complex pathophysiology of asthma. The hope is that asthma biologic therapies will eventually be tailored to an individual's asthma phenotype. With more than 300 million people worldwide affected by asthma and with roughly 5% to 10% of this population living with severe, uncontrolled asthma, the need for new biologic therapies is great. Conclusion The introduction of each new biologic therapy into clinical trials has been associated with great anticipation, but the outcome of these trials, in many cases, has led to disappointment. Given the lack of overwhelming positive responses, these results have emphasized that asthma is a complex clinical syndrome with multiple underlying genotypes and clinical phenotypes. It has become abundantly clear that it is very unlikely that there is one "magic bullet" to cure all patients with asthma.

UR - http://www.scopus.com/inward/record.url?scp=84893124137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893124137&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2013.12.013

DO - 10.1016/j.anai.2013.12.013

M3 - Article

C2 - 24468249

AN - SCOPUS:84893124137

VL - 112

SP - 108

EP - 115

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 2

ER -